Maya Mundelboim
Maya is an R&D Research Associate at PanTher Therapeutics. She is a recent graduate of the University of Massachusetts Amherst.
Prior to joining PanTher, Maya excelled academically achieving Dean’s List recognition from 2019 to 2023 and obtained hands-on experience as an intern at Amgen.
Maya holds a BS in Biomedical Engineering.
Chelsea Reinhold
Chelsea Reinhold is providing Clinical Operations Support to PanTher Therapeutics where she is focused on clinical trial design, strategy, and execution for current and upcoming studies. Chelsea has dedicated her career on bringing novel products to market in the oncology space.
Prior to PanTher Therapeutics, Chelsea served as Senior Clinical Project Manager at Instylla where she wore many hats including managing the first IDE study for a liquid embolic indicated for tumor embolization. Before that, she led the post-market clinical department at Augmenix, acquired by Boston Scientific for $500M+. Augmenix created a hydrogel indicated to space the rectum away from the prostate for men receiving prostate cancer radiation therapy. Chelsea was also involved in researching secondary indications for hydrogel spacers including between the pancreas and duodenum for pancreatic cancer, which resulted in a completed pilot study at Massachusetts General Hospital, MD Anderson Cancer Center, and Johns Hopkins Hospital.
Chelsea holds an MS degree in Clinical Research from Massachusetts College of Pharmacy and Health Sciences and a BS in Molecular and Cellular Biology from the University of Connecticut.
David Mackey
David Mackey is a senior finance and operations executive with a 20-year track record of success building, leading, and advising businesses in all phases of the corporate life cycle. In addition to serving as the Chief Financial Officer of Catalyst Health Ventures (CVH), he has been a strategic, financial, and operational advisor to PanTher Therapeutics since 2020.
Prior to joining the PanTher Therapeutics, David served as President and Chief Financial Officer of Lantos Technologies, where he led numerous strategic financings and was responsible for business and manufacturing operations, and Chief Financial Officer and Vice President, Business Development of AgNovos Healthcare, where he designed and built out the financial and operational infrastructure. Before that, he served as Vice President, Investment Banking at J.P. Morgan.
David began his career as a corporate attorney at Gibson, Dunn & Crutcher. He holds a JD from the University of Pennsylvania Law School and a BA in Journalism from Colorado State University.